Skip to main content
. 2021 Nov 24;12(11):1009–1022. doi: 10.5306/wjco.v12.i11.1009

Table 3.

Progression-free survival (according to the CHAARTED and STAMPEDE definitions of progressive disease) age, PSA, comorbidities and bone metastases


Number of patients
Number of events
HR, 95%CI, P value (univariate)
HR, 95%CI, P value (multivariate)
Age, yr (median)
≤ 68 48 21 1.00 1.00
> 68 46 15 0.78, 0.40-1.51, 0.45 0.83, 0.42-1.67, 0.61
PSA (median)
≤ 180 48 12 1.00 1.00
> 180 46 24 2.86, 1.39-5.87, 0.0041 2.51, 1.21-5.19, 0.013
Comorbidities
No 44 15 1.00 1.00
Yes 50 21 1.15, 0.59-2.23, 0.68 1.19, 0.60-2.36, 0.63
Distant metastases
No 19 3 1.00 1.00
Yes 75 33 3.36, 1.03-10.96, 0.045 2.60, 0.78-8.65, 0.12